HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.

AbstractPURPOSE:
Although metabolic changes make diagnosis of insulinoma relatively easy, surgical removal is hampered by difficulties in locating it, and there is no efficient treatment for malignant insulinoma. We have previously shown that the high density of glucagon-like peptide-1 receptors (GLP-1R) in human insulinoma cells provides an attractive target for molecular imaging and internal radiotherapy. In this study, we investigated the therapeutic potential of [Lys(40)(Ahx-DTPA-(111)In)NH(2)]-Exendin-4, an (111)In-labeled agonist of GLP-1, in a transgenic mouse model of human insulinoma.
EXPERIMENTAL DESIGN:
[Lys(40)(Ahx-DTPA-(111)In)NH(2)]-Exendin-4 was assessed in the Rip1Tag2 mouse model of pancreatic beta-cell carcinogenesis, which exhibits a GLP-1R expression comparable with human insulinoma. Mice were injected with 1.1, 5.6, or 28 MBq of the radiopeptide and sacrificed 7 days after injection. Tumor uptake and response, the mechanism of action of the radiopeptide, and therapy toxicity were investigated.
RESULTS:
Tumor uptake was >200% injected activity per gram, with a dose deposition of 3 Gy/MBq at 40 pmol [Lys(40)(Ahx-DTPA-(111)In)NH(2)]-Exendin-4. Other GLP-1R-positive organs showed > or =30 times lower dose deposition. A single injection of [Lys(40)(Ahx-DTPA-(111)In)NH(2)]-Exendin-4 resulted in a reduction of the tumor volume by up to 94% in a dose-dependent manner without significant acute organ toxicity. The therapeutic effect was due to increased tumor cell apoptosis and necrosis and decreased proliferation.
CONCLUSIONS:
The results suggest that [Lys(40)(Ahx-DTPA-(111)In)NH(2)]-Exendin-4 is a promising radiopeptide capable of selectively targeting insulinoma. Furthermore, Auger-emitting radiopharmaceuticals such as (111)In are able to produce a marked therapeutic effect if a high tumor uptake is achieved.
AuthorsAndreas Wicki, Damian Wild, Daniel Storch, Christian Seemayer, Martin Gotthardt, Martin Behe, Stefan Kneifel, Michael J Mihatsch, Jean-Claude Reubi, Helmut R Mäcke, Gerhard Christofori
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 13 Issue 12 Pg. 3696-705 (Jun 15 2007) ISSN: 1078-0432 [Print] United States
PMID17575235 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • (Lys(40)(Ahx-DTPA-111In)NH2)exendin-14
  • GLP1R protein, human
  • Glp1r protein, mouse
  • Glucagon-Like Peptide-1 Receptor
  • Indium Radioisotopes
  • Organometallic Compounds
  • Peptides
  • Radiopharmaceuticals
  • Receptors, Glucagon
  • Pentetic Acid
Topics
  • Animals
  • Cell Proliferation (drug effects)
  • Female
  • Glucagon-Like Peptide-1 Receptor
  • Indium Radioisotopes (pharmacokinetics, therapeutic use)
  • Insulinoma (diagnostic imaging, metabolism)
  • Male
  • Mice
  • Mice, Transgenic
  • Organometallic Compounds (pharmacokinetics, therapeutic use)
  • Pancreatic Neoplasms (diagnostic imaging, metabolism)
  • Pentetic Acid (pharmacokinetics, therapeutic use)
  • Peptides (pharmacokinetics, therapeutic use)
  • Radionuclide Imaging
  • Radiopharmaceuticals (pharmacokinetics, therapeutic use)
  • Receptors, Glucagon (metabolism)
  • Tissue Distribution

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: